Onconetix Inc Ordinary Shares ONCO 深 沪
等待开盘 10-02 09:30:00 美东时间
2.96
-0.150
-4.82%
华盛通- 最 高3.1947
- 今 开3.06
- 成交量 7.54万股
- 最 低 2.945
- 昨 收 3.11
- 总市值 457.53万
- 52周最高 552.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.45
- 委 比 -83.23%
- 总股本 154.57万
- 历史最高 309060.00
- 量 比 0.21
- 振 幅 8.03%
- 历史最低 2.945
- 每 手 1
- 风险率 120.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Onco-Innovations Advances Preclinical Program with Nucro-Technics Collaboration
Onco-Innovations Ltd. ( ($TSE:ONCO) ) has provided an announcement. Onco-Innova...
09-30 03:08
Onconetix Completes $12.9M Private Placement
Onconetix ( ($ONCO) ) has issued an announcement. On September 22, 2025, Oncone...
09-26 21:15
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
Onconetix, Inc. completed a $12.9 million private placement of Series D Convertible Preferred Stock and warrants, with $9.3 million paid in cash and $3.6 million used to offset debts. The Series D Preferred Stock is convertible into 4.36 million shares of common stock, and the warrants have an exercise price of $3.6896 per share. Proceeds will be used to terminate a previous business combination with Ocuvex and for working capital. Onconetix also...
09-26 12:30
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
Onconetix, Inc. and Ocuvex Therapeutics, Inc. have mutually terminated their merger agreement, deciding to pursue independent paths. Both companies remain committed to advancing their missions and delivering value to patients. Ocuvex has received its New Jersey state pharmaceutical license and is set to launch Omlonti commercially in the coming weeks. Onconetix and Ocuvex appreciate the collaborative spirit during the merger discussions.
09-26 12:15
Onconetix's Proteomedix Licenses Key Antibody Technology To Immunovia For Pancreatic Cancer Test; In Return, Immunovia Will Make Payments Totaling $700K To Proteomedix In 2025 And 2026, As Well As Pay A 3% Royalty On Net Sales Of PancreaSure And Any Other Products Incorporating The Licensed Intellectual Property From 2026 To 2032
Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology,
09-22 20:16
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
Onconetix, Inc. subsidiary Proteomedix AG has signed a licensing agreement with Immunovia AB, a Swedish pancreatic cancer diagnostics company. The agreement allows Immunovia to use Proteomedix's master cells and intellectual property for producing antibodies related to three biomarkers in the PancreaSure test. Immunovia will pay $700,000 in 2025-2026 and a 3% royalty on net sales from 2026 to 2032. Proteomedix CEO Beat Rheiner expressed pride in ...
09-22 12:00
Onco-Innovations Partners with Dalton Pharma for Nanoparticle Manufacturing
The latest announcement is out from Onco-Innovations Ltd. ( ($TSE:ONCO) ). Onco...
09-20 06:38
Onco-Innovations to Lead Colorectal Cancer Precision Oncology Forum
Onco-Innovations Ltd. ( ($TSE:ONCO) ) has provided an update. Onco-Innovations ...
09-13 06:43
Designer Brands Inc. Reports Second Quarter 2025 Financial Results
Sequential comparable sales improvement from first quarter of 2025 underscores strength and efficacy of strategies Delivered positive diluted earnings per share ("EPS") of $0.22 and positive...
09-09 18:45
Onconetix Issues Promissory Notes to Keystone Capital
An update from Onconetix ( ($ONCO) ) is now available. On August 28, 2025, Onco...
09-05 04:36
